Literature DB >> 33006405

The pMy vector series: A versatile cloning platform for the recombinant production of mycobacterial proteins in Mycobacterium smegmatis.

Katherine S H Beckham1, Sonja Staack1, Matthias Wilmanns1,2, Annabel H A Parret1.   

Abstract

Structural and biophysical characterization of molecular mechanisms of disease-causing pathogens, such as Mycobacterium tuberculosis, often requires recombinant expression of large amounts highly pure protein. For the production of mycobacterial proteins, overexpression in the fast-growing and non-pathogenic species Mycobacterium smegmatis has several benefits over the standard Escherichia coli expression strains. However, unlike for E. coli, the range of expression vectors currently available is limited. Here we describe the development of the pMy vector series, a set of expression plasmids for recombinant production of single proteins and protein complexes in M. smegmatis. By incorporating an alternative selection marker, we show that these plasmids can also be used for co-expression studies. All vectors in the pMy vector series are available in the Addgene repository (www.addgene.com).
© 2020 The Authors. Protein Science published by Wiley Periodicals LLC on behalf of The Protein Society.

Entities:  

Keywords:  Mycobacterium smegmatis; mycobacteria; protein expression; recombinant proteins

Year:  2020        PMID: 33006405      PMCID: PMC7679961          DOI: 10.1002/pro.3962

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


green fluorescent protein hexahistidine tag hygromycin immobilized metal affinity chromatography kanamycin seamless ligation cloning extract tobacco etch virus

INTRODUCTION

The Gram‐positive genus Mycobacterium includes several human pathogens, including Mycobacterium tuberculosis (Mtb). Mtb is listed by the World Health Organization as the leading cause of death from an infectious agent and led to 1.5 million deaths in 2019 alone. The increase in multi‐drug resistant strains of Mtb remains a public health crisis and the need for novel antibiotic therapies to treat Mtb is a priority. The growing importance of Mtb and other mycobacterial pathogens to human health has led to an intensive effort from several structural biology consortia to investigate the structure and function of mycobacterial proteins. , Despite these efforts, currently only approximately 15% of the Mtb proteome has been structurally characterized, in part due to the challenge of Mtb protein production. The production of large amounts of highly pure, properly folded and functional protein remains a bottle neck in the structural biology pipeline. Escherichia coli is typically the standard expression host for protein production and there are a variety of modified strains available that are optimized for tackling challenging proteins. However, studies have shown that for the production of mycobacterial proteins, expression in standard E. coli strains is only successful in one third of cases. , There are several factors that may limit the suitability of E. coli for the production of mycobacterial proteins, such as the mismatch in codon usage between mycobacterial genes and the E. coli translation machinery caused by the higher GC bias in Mtb genes. , In addition, the absence of key cofactors, post‐translational modifications and chaperones in E. coli may further impede the production of mycobacterial proteins. Owing to these deficiencies, many groups have turned to the fast‐growing, non‐pathogenic mycobacterial expression host, Mycobacterium smegmatis. The benefits of the use of M. smegmatis as an expression host, leading to an improved yield, solubility and functionality of purified proteins has been reported in several studies. , , Despite the advantages of mycobacterial protein production using M. smegmatis, the limited range of genetic tools compared to those available for E. coli has restricted the widespread use of this expression host. However, several groups continue to develop expression strains and optimize expression vectors with different features such as induction system, promoter strength and purification tags. , , , , , There are two principle M. smegmatis strains used for protein expression, M. smegmatis mc24517 and mc2155 groEL1ΔC. M. smegmatis mc24517 has been modified to allow the expression of T7‐promoter based systems following the incorporation of the bacteriophage T7 RNA polymerase. Several vector systems have been developed for use in this strain including, pYUB1062 and pYUB1049. Further modified versions allow for a choice of N‐ or C‐ terminal hexahistidine (His6) tag positioning (pYUB28b), expression of a GFP fusion protein (pYUB1062‐GFP) or for the co‐expression of two protein targets (pYUBDuet). The mc2155 groEL1ΔC strain has been modified to reduce the co‐purification of GroEL1 chaperone protein following the deletion of its histidine‐rich C‐terminus and can be used for expression of vectors carrying conditional promoter systems, such as acetamidase, tetracycline or arabinose. The acetamidase promoter of M. smegmatis can be induced by the addition of acetamide, and several vector systems utilize this promoter to drive protein expression, including the pSD and pMyNT/ pMyC vectors. Several modified variants of these vectors exist, including the pMyCA vector, which contains a minimized acetamidase promoter. , Induction of the acetamidase promoter leads to a high level of protein expression, which in the case of toxic protein production may not be desirable. In E. coli, the arabinose‐inducible promoter (PBAD) enables tightly controlled and tunability of gene expression. The arabinose promoter system is currently not widely used in M. smegmatis, but the tunability of this promoter prompted us to further explore its use for protein expression. The aim of this work was to further expand the versatility of the pMyNT and pMyC vectors, which have been successfully used for both the production of single soluble proteins as well as protein complexes expressed from a single operon. , , The pMyNT and pMyC vectors are shuttle vectors which can be propagated in E. coli cells for ease of manipulation, due to the presence of the OriE and the OriM origins of replication (Ori). These Ori are used for replication in E. coli and M. smegmatis, respectively. Both vectors encode a His6 tag at the N‐terminus (pMyNT) or at the C‐terminus (pMyC) and a hygromycin resistance marker for selection. Here we describe the modification of the pMyNT and pMyC vectors generating variants with an alternative selection marker and an arabinose‐inducible promoter resulting in the “pMy vector series”. Using fluorescent reporter proteins, we show that the pMy vectors can be used for the overexpression of a single protein and in combination for the production of multiple targets. In addition, we demonstrate the tunability of the PBAD arabinose‐based promoter, which may prove advantageous for the production of toxic proteins. The pMy vector series has been deposited with Addgene (www.addgene.com).

RESULTS

Construction of

To expand the existing repertoire of M. smegmatis expression vectors and create more tools for the production of mycobacterial vectors, we created variants of the existing pMyNT and pMyC vectors, which were previously generated by our group. First we exchanged the existing acetamidase promoter present in both the pMyNT and pMyC for the arabinose‐inducible promoter from the pBAD vector (PBAD), with the aim of producing a vector with tunable expression. Using Gibson cloning methods, the linearized fragments of the pMyC and pMyNT vectors without the acetamidase promoter were ligated with the PBAD arabinose promoter producing the arabinose‐inducible, hygromycin‐resistant vectors with a N‐terminal His6 or C‐terminal His6 tag, pMyBADNT and pMyBADC, respectively. In addition, we extended the co‐compatibility of the pMy vectors by including the kanR gene, which is widely used in other M. smegmatis vectors. Utilizing Gibson cloning approaches again, vector backbones of pMyNT, pMyC, pMyBADNT, and pMyBADC were amplified to omit the hygromycin resistance cassette, these backbone fragments were then ligated with the kanamycin resistance cassette, thus generating pMyNTkan, pMyCkan, pMyBADNTkan, and pMyBADCkan. An overview of the pMy vectors and their respective properties are outlined in Figure 1. All of the vectors produced in this study have been made available on Addgene (www.addgene.org) with their catalog numbers listed in Figure 1d.
FIGURE 1

The pMy vector series. (a) Overview of the features of the pMy vectors, highlighting the arrangement of the promoter and resistance genes (maps not shown to scale). (b) Multiple cloning site of the pMy vectors with an N‐terminal hexahistidine tag (His6) followed by a TEV cleavage site. (c) Multiple cloning site of the pMy vectors with a C‐terminal hexahistidine tag (His6). The unique restriction sites NcoI and HindIII are indicated. (d) Table summarizing the properties of the pMy vectors

The pMy vector series. (a) Overview of the features of the pMy vectors, highlighting the arrangement of the promoter and resistance genes (maps not shown to scale). (b) Multiple cloning site of the pMy vectors with an N‐terminal hexahistidine tag (His6) followed by a TEV cleavage site. (c) Multiple cloning site of the pMy vectors with a C‐terminal hexahistidine tag (His6). The unique restriction sites NcoI and HindIII are indicated. (d) Table summarizing the properties of the pMy vectors As for the original pMyNT vector, all pMy vectors with N‐terminal His6 tags are preceded by a tobacco etch virus (TEV) cleavage site allowing the removal of the tag following immobilized metal affinity chromatography (IMAC). The pMy vectors derived from the original pMyC vector with a C‐terminal His6 tag do not include the TEV cleavage site due to the fact that following cleavage with TEV protease, five additional amino acids from the TEV recognition site remain, comparable in length to the His6 tag itself. The multiple cloning site (MCS) of the pMy vectors all contain the unique restriction sites NcoI and HindIII that can be used for linearizing the plasmids for ligation with a gene of interest using either restriction enzyme (RE) based cloning methods or ligation‐independent cloning methods (Figure 1b,c). However, the limited number of unique restriction sites in the pMy vectors restricts the use of RE based cloning. Therefore, we primarily use ligation‐independent cloning methods such as seamless ligation cloning methods (SliCE) or Gibson assembly methods for cloning genes into the pMy vectors. The recommended primer extension sequences for use with these methods for each of the pMy vectors are listed in Table S2.

The level of protein expression from each of the pMy plasmid variants was evaluated using green fluorescent protein (GFP), which has been successfully used to monitor protein expression levels in other M. smegmatis vector systems. The GFP gene was amplified using the primers listed in Table S3 and ligated into each of the pMy vectors using SliCE. For protein production, we routinely use the M. smegmatis mc2155 groEL1ΔC strain that has been optimized for purification of proteins by IMAC methods, and therefore we tested the activity of the vectors in this strain. However as the pMyNT and pMyC vectors are compatible with other M. smegmatis strains, it is likely that the new pMy variants produced in this study will also be compatible as the vector backbone is largely unchanged. M. smegmatis cultures were grown to an OD600 of 1 in 7H9 expression medium before induction with either 1% acetamide or 1% arabinose. A concentration of 1% of the inducer molecule was chosen as higher concentrations of acetamide lead to an increase in cell aggregation reducing the accuracy of the fluorescence measurements. The amount of GFP produced in whole cells was measured using a plate reader following 18‐hour induction with either arabinose or acetamide, as appropriate (Figure 2). The highest level of GFP expression was detected from the pMyNT and pMyNTkan vectors, which encode the acetamidase promoter and have the His6 tag positioned at the N‐terminus. In comparison to the pMyC and pMyCkan vectors (acetamidase promoter, C‐terminal His6 tag) the pMyNT and pMyNTkan vectors displayed approximately a three‐fold higher level of GFP fluorescence. This difference was also observed for pMy vectors with arabinose inducible promoters when comparing GFP expression between the vectors with an N‐terminal His6 tag (pMyBADNT and pMyBADNTkan) and the C‐terminal His6 tag (pMyBADC and pMyBADCkan). This difference was significant for all vector variants (p = .0001) and suggests that the N‐terminal position of the His6 tag leads to more effective translation, which has been similarly observed in other systems. When comparing the pMy vectors with the same affinity tag position (e.g., pMyNT vs pMyBADNT), the acetamidase‐based vectors produce a significantly higher amount of GFP (p < .001). Additionally, there was no significant difference in the level of protein production between the hygromycin‐ and kanamycin‐resistant variants, indicating that the choice of selection marker did not impact protein production.
FIGURE 2

GFP expression using the pMy vectors in M. smegmatis. M. smegmatis cultures expressing pMy vectors encoding GFP2+ were induced at an OD600nm of 1 with either 1% acetamide or arabinose, as appropriate. Determination of the GFP expression was calculated as relative fluorescence unit (RFU). All data were averaged from three independent samples of each time point. Samples were taken before and 24 hr after addition of inducer. Error bars depict standard deviation of three independent experiments

GFP expression using the pMy vectors in M. smegmatis. M. smegmatis cultures expressing pMy vectors encoding GFP2+ were induced at an OD600nm of 1 with either 1% acetamide or arabinose, as appropriate. Determination of the GFP expression was calculated as relative fluorescence unit (RFU). All data were averaged from three independent samples of each time point. Samples were taken before and 24 hr after addition of inducer. Error bars depict standard deviation of three independent experiments As protein overexpression can be toxic to the host cell, an uninduced sample was included to monitor the level of background or “leaky” expression from the vectors. For all vectors the level of background expression was below 0.5% of the total amount of GFP being produced compared with the induced sample. Thus, even at high inducer concentrations both the acetamidase promoter and PBAD promoter appear to be tightly regulated in M. smegmatis mc2155 groEL1ΔC. To investigate the tunability of the acetamidase (pMyNT) and PBAD (pMyBADNT) promoters in M. smegmatis, we followed the expression of GFP over time using a range of inducer concentrations (Figure 3). At the concentrations tested, induction of the acetamidase promoter leads to a rapid increase in GFP production, which does not appear to be dependent on the inducer concentration. While the highest concentration of acetamide used was 1%, decreasing the acetamide levels did not significantly reduce the level of GFP expression at the concentrations used in this study (Figure 3a). In contrast, increasing the concentration of arabinose proportionally increased the level of GFP expression from the pMyBADNT vector (Figure 3b). At the final 24 hr time point, the level of GFP produced from the different arabinose concentrations was significantly different (p < .001). Together these results indicate that PBAD promoter is more tightly regulated than the acetamidase promoter in M. smegmatis. The tunability of the pBAD promoter in the pMy vectors could be exploited for the production of toxic proteins where unregulated levels of protein expression may lead to cell death.
FIGURE 3

Time course of GFP expression in M. smegmatis following induction of the acetamidase (a) or arabinose promoters (b) with a range of inducer concentrations. Cultures of M. smegmatis transformed with either pMyNT‐GFP (a) or pMyBADNT‐GFP (b) were induced at an OD600nm of 1 with acetamide or arabinose, respectively. The concentration (v/v) of inducer used varied between 0.05–1%, uninduced cultures (0%) indicate the level of unregulated background expression. GFP fluorescence was monitored at various time points after induction (0 hr). Error bars indicate the standard deviation of three independent experiments

Time course of GFP expression in M. smegmatis following induction of the acetamidase (a) or arabinose promoters (b) with a range of inducer concentrations. Cultures of M. smegmatis transformed with either pMyNT‐GFP (a) or pMyBADNT‐GFP (b) were induced at an OD600nm of 1 with acetamide or arabinose, respectively. The concentration (v/v) of inducer used varied between 0.05–1%, uninduced cultures (0%) indicate the level of unregulated background expression. GFP fluorescence was monitored at various time points after induction (0 hr). Error bars indicate the standard deviation of three independent experiments One of the aims of generating the pMy vector series with different antibiotic selection markers was to facilitate co‐expression studies. To test whether a combination of pMy vectors could successfully express multiple proteins, we monitored the expression of GFP and mCHERRY simultaneously by using the corresponding excitation and emission wavelengths for each protein. mCHERRY was cloned into pMyNTkan, pMyBADkan using the primers listed in Table S3 with SliCE cloning methods as described above. Different combinations of pMy plasmids encoding either GFP or mCHERRY were co‐transformed into M. smegmatis mc2155 groEL1ΔC by electroporation and co‐transformants were selected using hygromycin and kanamycin. To test the level of co‐expression from two plasmids carrying the acetamidase promoter pMyNT‐GFP and pMyNTkan‐mCHERRY were co‐transformed (Figure 4a). Similarly, to test co‐expression from two pMy plasmids carrying the arabinose promoter system pMyBAD‐GFP was combined with pMyBADkan‐mCHERRY (Figure 4b). Finally, pMyBAD‐GFP was combined with pMyNTkan‐mCHERRY to test the co‐expression from the two different protomer systems (Figure 4c). For all combinations fluorescent protein expression was monitored 18 hr following induction with 1% (v/v) acetamide and /or arabinose, as appropriate. For all vector combinations, the production of GFP and mCHERRY increased after induction showing that co‐expression from two independent pMy vectors is possible. To compare the protein amounts produced during a co‐expression experiment to the production from a single vector, the amount of GFP and mCHERRY produced during co‐expression has been shown relative to the amount produced from the expression of the single protein from the corresponding vector. For example, the amount of GFP produced in the co‐expression of pMyNT‐GFP and pMyNTkan‐mCHERRY (Figure 4a) has been normalized to the amount of GFP produced by expressing pMyNT‐GFP alone using the same conditions. Based on the normalized RFU readings the amount of GFP or mCHERRY produced in a co‐expression experiment reduces by approximately 35%–55% compared to single expression. There was no significant difference between the level of GFP or mCHERRY produced by the different vector combinations, indicating that none of the pMy plasmids were expressed preferentially over the other. In summary, the expression of the two fluorescent proteins from independent vectors demonstrates that pMy vectors encoding different antibiotic resistance markers and promoter systems can be combined for co‐expression studies.
FIGURE 4

Co‐expression of GFP and mCHERRY in M. smegmatis from the pMy vectors. M. smegmatis was co‐transformed with different combinations of pMy vectors encoding GFP or mCHERRY fluorescent protein. Fluorescence of GFP and mCHERRY was measured 18 hr after the addition of the appropriate inducer to a final concentration of 1% (v/v). The mean fluorescence values have been normalized to the amount of GFP/mCHERRY produced following expression from a single vector under the same conditions, shown as relative fluorescence units (RFU). Error bars depict the standard deviation of three independent experiments. (a) Co‐expression of two pMy vectors carrying an acetamidase promoter (pMyNT‐GFP and pMyNTkan‐mCHERRY). (b) Co‐expression of two pMy vectors carrying an arabinose promoter (pMyBADNT‐GFP and pMyBADNTkan‐mCHERRY). (c) Combination of one pMy vector carrying an arabinose promoter (pMyBAD‐GFP) and one pMy vector with an acetamidase promoter (pMyNTkan‐mCHERRY)

Co‐expression of GFP and mCHERRY in M. smegmatis from the pMy vectors. M. smegmatis was co‐transformed with different combinations of pMy vectors encoding GFP or mCHERRY fluorescent protein. Fluorescence of GFP and mCHERRY was measured 18 hr after the addition of the appropriate inducer to a final concentration of 1% (v/v). The mean fluorescence values have been normalized to the amount of GFP/mCHERRY produced following expression from a single vector under the same conditions, shown as relative fluorescence units (RFU). Error bars depict the standard deviation of three independent experiments. (a) Co‐expression of two pMy vectors carrying an acetamidase promoter (pMyNT‐GFP and pMyNTkan‐mCHERRY). (b) Co‐expression of two pMy vectors carrying an arabinose promoter (pMyBADNT‐GFP and pMyBADNTkan‐mCHERRY). (c) Combination of one pMy vector carrying an arabinose promoter (pMyBAD‐GFP) and one pMy vector with an acetamidase promoter (pMyNTkan‐mCHERRY)

DISCUSSION

The production of mycobacterial proteins for structural, functional and biochemical studies remains an important step in the drug discovery pipeline. The production of mycobacterial proteins in M. smegmatis is becoming more common owing to the advantages of using a more native expression host over the traditional E. coli strains. , , , The aim of this work was to further expand the tools available for recombinant protein expression in M. smegmatis. The pMy vector series derives from the pMyNT and pMyC vectors that have been used in the mycobacterial field over the past decade. , , Induction of protein expression from the acetamidase promoter is an established system in M. smegmatis and leads to high levels of target protein expression. However, when producing proteins that are toxic to the cell such as membrane proteins, toxins or DNA binding proteins it can often be advantageous to regulate the level of protein overexpression. In E. coli the arabinose inducible promoter system, which includes the pBAD promoter and the AraC regulator has been successfully exploited to tightly regulate protein expression and its activity in M. smegmatis has also been demonstrated. It is for this reason that we introduced the arabinose promoter system into the pMy vectors. By comparing the induction of GFP expression from both the acetamidase promoter (pMyNT) and the arabinose‐inducible promoter (pMyBADNT), we showed that induction with different concentrations of arabinose is correlated with the level of GFP expression. This is in contrast to induction of the acetamidase promoter, where all concentrations tested resulted in a similar level of GFP fluorescence. The tuneability of the arabinose promoter in M. smegmatis could provide a useful alternative to the acetamidase promoter for the production of toxic proteins and allow better control of the production of protein complexes where the correct stoichiometry of the different components may be essential for solubility. To test the overall performance of pMy vectors we examined the level of GFP production from each of the vectors in the pMy series following induction with either acetamide, arabinose, or no inducer as a control. As expected, the acetamidase‐based vectors (pMyNT, pMyNTkan, pMyC and pMyCkan) produced higher amounts of GFP compared to the arabinose‐inducible vectors (pMyBADNT, pMyBADMNTkan, pMyBADC and pMyBADCkan). The significant reduction in the amount of GFP produced from the C‐terminally tagged vectors was unexpected, but has been observed for other expression systems which show an increased production of target proteins with N‐terminal fusions. Recent work by Vergara et al., produced a modified pMyC variant with a reduced acetamidase regulon which increased protein production, although whether this change resulted in a similar level of expression as from the pMyNT vectors was not tested in this work. Using high concentrations of inducer, the pMyBAD vectors produced lower quantities of GFP compared to the acetamide‐based vectors. This correlates with the previous reports of the low level of activity of the arabinose‐inducible promoter system in M. smegmatis. However, owing to the tunability of this promoter we propose that the pMyBAD vectors would be beneficial in cases where the target protein is toxic, as even low concentrations of acetamide leads to high levels of protein expression. Under these expression conditions, both the acetamidase‐ and arabinose‐inducible systems have a low level of background expression following comparison of the induced to the uninduced samples. The low level of “leaky expression” contrasts with previous observations on the acetamide inducible systems using, for example, the pYUB1062 vectors in the M. smegmatis strain mc24517. This may reflect differences in the plasmid, M. smegmatis strain or growth media conditions. In addition to creating expression vectors where the level of recombinant protein production can be as tightly regulated as for the pMyBAD vectors, we also aimed to facilitate co‐expression studies by introducing an alternative selection marker, kanamycin. The kanamycin‐resistant pMy variants show the same expression levels as the hygromycin‐resistant variants, and as kanamycin is significantly cheaper than hygromycin it may be more accessible to some laboratories. Here we show that the co‐expression of GFP and mCHERRY from the combination of pMy vectors with different promoter systems is possible. The combination of the tightly regulated pBAD promoter with the highly expressed acetamidase promoter may provide a useful strategy for the expression of toxin‐antitoxin systems where the cytotoxic protein component be expressed at a lower level than is anti‐toxin counterpart, however this has not been tested as part of this work. In summary, this work contributes additional tools for the production of recombinant proteins in M. smegmatis. As more tools become available, we hope to see further development of specific M. smegmatis expression strains for the production of recombinant proteins, as for example the C41 strain for membrane protein production in E. coli (Lucigen). The pMy vector series could be further modified to include different purification tags to expand the applications of these vectors for the production of multi‐protein complexes. The production of mycobacterial proteins for biochemical, biophysical and structural studies remains a key step in the search for novel anti‐mycobacterial therapies. We anticipate that the expansion of the pMy vector series will be a useful tool for the community.

MATERIALS AND METHODS

Reagents, bacterial strains, and growth conditions

All cloning and plasmid propagation were conducted in E. coli DH5α‐T1R (Life Technologies) using standard protocols. E. coli was transformed by conventional heat shock transformation and grown in Lennox Broth (LB) or LB agar plates (Carl Roth). The seamless ligation cloning extract (SLiCE) was produced from the E. coli DH10B‐PPY strain. In liquid cultures M. smegmatis mc2155 groEL1ΔC was grown in Middlebrook 7H9 medium (BD Biosciences) supplemented with 0.2% (w/v) glucose (Carl Roth), 342 mM NaCl), 0.05% (v/v) Tween‐80 (Carl Roth) and 0.2% (v/v) glycerol (Carl Roth). Alternatively, the solid growth media used was 7H10 agar (Sigma‐Aldrich) supplemented with 10% albumin–dextrose saline (ADS: 5% (w/v) BSA cold ethanol fraction, pH 5.2, ≥96% (Sigma‐Aldrich), 2% (w/v) glucose (Carl Roth), 342 mM NaCl), 0.05% (v/v) Tween‐80 (Carl Roth) and 0.2% (v/v) glycerol (Carl Roth). All bacterial strains were grown at 37°C. Where required the growth media was supplemented with 94 μM hygromycin B (Carl Roth) or 35 μM kanamycin (Sigma‐Aldrich). The expanded pMy vector series is based on the previously described pMyNT and pMyC vectors which are derived from pSD31. The sequences of the primers used in the construction of the pMy vectors are listed in Table S1. PCR amplification was performed with Q5® High‐Fidelity DNA Polymerase according to the manufacturer's instructions (New England Biolabs) and DNA fragments were purified with the Wizard SV Gel and PCR Clean‐up System (Promega). The different pMy vectors were created using Gibson assembly methods to generate variants encoding kanamycin resistance or the PBAD promoter. The acetamidase promoter composed of the amiC, amiA, amiD and amiS genes encoded in in the pMyNT and pMyC vectors was replaced by the arabinose promoter (araC gene) from the pBAD/His (Thermo Fischer) vector using Gibson cloning producing pMyBADNT and pMyBADC. The parent plasmids pMyNT and pMyC were linearized by PCR to generate the “vector insert” using the primers listed in Table S1. The PBAD promoter was amplified by PCR from the PBAD/His (Thermo Fischer) using the corresponding “insert” primers listed in Table S1. The PCR products were purified and ligated using Gibson Assembly Master Mix (New England Biolabs) as per the manufacturer's instructions, using the recommended vector concentration of 50 ng and a two‐fold molar excess of insert. Ligation mixtures were transformed into E. coli DH5α‐T1R (Life Technologies) by heat shock transformation and plated onto LBagar plates containing hygromycin and incubated at 37°C overnight. The resultant plasmids, pMyBADNT and pMyBADC were sequence verified (Eurofins Genomics). To make kanamycin resistant variants of the pMyNT, pMyC, pMyBADNT, and pMyBADC the hygromycin B (hygR) resistance marker was exchanged for the for the kanR marker. The kanR gene was amplified by PCR using the pMV306 vector as template using the “insert” primers listed in Table S1 for each of the corresponding pMy vectors. Linear fragments of the pMyNT, pMyC, pMyBADNT, and pMyBADC vectors without the hygR gene were generated by PCR amplification using the “vector” primers listed in Table S1. Each of the vector backbone fragments was ligated with the complementary kanR product using the Gibson Assembly Master Mix (New England Biolabs) as described above. These reactions resulted in pMyNTkan, pMyCkan, pMyBADNTkan, and pMyBADCkan plasmids which were all sequence verified (Eurofins Genomics). The pMy plasmids generated in this study, pMyNTkan, pMyCkan, pMyBADNTkan, pMyBADCkan, pMyBADNT, and pMyBADCkan have been deposited on Addgene (www.addgene.com). Expression constructs were generated using SliCE cloning methods with the SliCE ligation mix prepared as described by Zhang et al. Vectors were linearized by restriction enzyme digestion with NcoI/HindIII followed by dephosphorylation using Antarctic phosphatase (New England Biolabs). Genes encoding the green fluorescent protein (GFPm2+) and red fluorescent protein (mCHERRY3) were synthesized and provided by Genscript using the sequences shown in Figure S1. The genes were amplified by PCR using Q5® High‐Fidelity DNA Polymerase (New England Biolabs). All primers used for the generation of plasmids used in this study are listed in Table S3. DNA fragments were purified with the Wizard SV Gel and PCR Clean‐up System (Promega). SliCE cloning reactions were performed using 50 ng linearized vector with a 5:1 (insert:vector) molar excess of purified insert. Ligation mixtures were transformed to E. coli DH5α‐T1R and transformants were selected on LB plates containing the appropriate antibiotic. Plasmid DNA was prepared using QIAprep Spin Miniprep kit (Qiagen) and sequence‐verified with vector‐specific primers (AP‐328, 5’‐CGCAGTTGTTCTCGCATACC‐3′ and pMyNT‐rev, 5′‐ TGGATCTCTCCGGCTTCAC‐3′) before transformation to M. smegmatis mc2155 groEL1ΔC. Electrocompetent M. smegmatis mc2155 groEL1ΔC were prepared as previously described.

Monitoring the expression of fluorescent proteins expressed from

To monitor protein expression from the pMy vectors in M. smegmatis, the fluorescent reporter proteins GFP2+ or mCHERRY were used. Expression constructs outlined in Table S3 were transformed into electrocompetent M. smegmatis and selected on 7H10 agar supplemented with either kanamycin or hygromycin, as appropriate. In the case of co‐expression studies, both plasmids were simultaneously transformed by electroporation into M. smegmatis and plated onto 7H10 agar plates supplemented with both kanamycin and hygromycin, (35 μM or 94 μM, respectively). Transformants were confirmed using colony PCR. M. smegmatis starter cultures were cultivated from freshly streaked colonies or glycerol stocks for grown for 3 days at 37°C with orbital shaking at 120 rpm. For small‐scale expression studies, a 1% volume of a starter culture was used to inoculate 50 ml of 7H9 expression medium. Cultures were grown to an OD600 of 1 and induced with varying concentrations of arabinose or acetamidase, as indicated. The first time point (0) was taken at the point of induction and several time points over 24 hr after induction, at each time point 200 μl of each culture was transferred from the 50 ml culture to a black FLUOTRAC flat bottomed 96 well plate (Greiner Bio‐One). The fluorescence of GFP or mCHERRY, or both in the case of co‐expression studies, was measured using a TECAN infinite M1000 plate reader. GFP fluorescence was measured at an excitation wavelength of 490 nm and an emission wavelength of 509 nm. For mCHERRY detection, an excitation wavelength of 587 nm and an emission wavelength of 610 nm was used. A gain value of 100 was used for all measurements. Statistical analysis of expression levels was performed using a Student's t‐test. For the analysis of the co‐expression of GFP and RFP, the values have been normalized to the 18 hr timepoint level of fluorescence (RFU) for the respective reporter.

AUTHOR CONTRIBUTIONS

Katherine Beckham: Conceptualization; formal analysis; funding acquisition; investigation; methodology; supervision; writing‐original draft; writing‐review and editing. Sonja Staack: Investigation; methodology. Matthias Wilmanns: Conceptualization; funding acquisition; resources; supervision; writing‐original draft; writing‐review and editing. Annabel Parret: Conceptualization; methodology; project administration; supervision; writing‐original draft; writing‐review and editing. Table S1 Oligonucleotides used in generation of the pMy vectors. Table S2. Primer extensions for gene of interest for SLiCE cloning. Table S3. Oligonucleotides used to generate the expression plasmids for this study. Click here for additional data file.
  32 in total

1.  The RD1 proteins of Mycobacterium tuberculosis: expression in Mycobacterium smegmatis and biochemical characterization.

Authors:  Sabine Daugelat; Jane Kowall; Jens Mattow; Dirk Bumann; Ralf Winter; Robert Hurwitz; Stefan H E Kaufmann
Journal:  Microbes Infect       Date:  2003-10       Impact factor: 2.700

2.  An inducible expression system permitting the efficient purification of a recombinant antigen from Mycobacterium smegmatis.

Authors:  J A Triccas; T Parish; W J Britton; B Gicquel
Journal:  FEMS Microbiol Lett       Date:  1998-10-15       Impact factor: 2.742

3.  Expression of Mycobacterium tuberculosis Rv1991c using an arabinose-inducible promoter demonstrates its role as a toxin.

Authors:  Paul Carroll; Amanda C Brown; Anna R Hartridge; Tanya Parish
Journal:  FEMS Microbiol Lett       Date:  2007-07-09       Impact factor: 2.742

4.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.

Authors:  S T Cole; R Brosch; J Parkhill; T Garnier; C Churcher; D Harris; S V Gordon; K Eiglmeier; S Gas; C E Barry; F Tekaia; K Badcock; D Basham; D Brown; T Chillingworth; R Connor; R Davies; K Devlin; T Feltwell; S Gentles; N Hamlin; S Holroyd; T Hornsby; K Jagels; A Krogh; J McLean; S Moule; L Murphy; K Oliver; J Osborne; M A Quail; M A Rajandream; J Rogers; S Rutter; K Seeger; J Skelton; R Squares; S Squares; J E Sulston; K Taylor; S Whitehead; B G Barrell
Journal:  Nature       Date:  1998-06-11       Impact factor: 49.962

Review 5.  The TB structural genomics consortium: a resource for Mycobacterium tuberculosis biology.

Authors:  T C Terwilliger; M S Park; G S Waldo; J Berendzen; L-W Hung; C-Y Kim; C V Smith; J C Sacchettini; M Bellinzoni; R Bossi; E De Rossi; A Mattevi; A Milano; G Riccardi; M Rizzi; M M Roberts; A R Coker; G Fossati; P Mascagni; A R M Coates; S P Wood; C W Goulding; M I Apostol; D H Anderson; H S Gill; D S Eisenberg; B Taneja; S Mande; E Pohl; V Lamzin; P Tucker; M Wilmanns; C Colovos; W Meyer-Klaucke; A W Munro; K J McLean; K R Marshall; D Leys; J K Yang; H-J Yoon; B I Lee; M G Lee; J E Kwak; B W Han; J Y Lee; S-H Baek; S W Suh; M M Komen; V L Arcus; E N Baker; J S Lott; W Jacobs; T Alber; B Rupp
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131

Review 6.  Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: the novel Fh8 system.

Authors:  Sofia Costa; André Almeida; António Castro; Lucília Domingues
Journal:  Front Microbiol       Date:  2014-02-19       Impact factor: 5.640

7.  Heterologous expression of mycobacterial Esx complexes in Escherichia coli for structural studies is facilitated by the use of maltose binding protein fusions.

Authors:  Mark A Arbing; Sum Chan; Liam Harris; Emmeline Kuo; Tina T Zhou; Christine J Ahn; Lin Nguyen; Qixin He; Jamie Lu; Phuong T Menchavez; Annie Shin; Thomas Holton; Michael R Sawaya; Duilio Cascio; David Eisenberg
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

Review 8.  Recombinant protein expression in Escherichia coli: advances and challenges.

Authors:  Germán L Rosano; Eduardo A Ceccarelli
Journal:  Front Microbiol       Date:  2014-04-17       Impact factor: 5.640

9.  A uniform cloning platform for mycobacterial genetics and protein production.

Authors:  Fabian M Arnold; Michael Hohl; Sille Remm; Hendrik Koliwer-Brandl; Sophia Adenau; Sasitorn Chusri; Peter Sander; Hubert Hilbi; Markus A Seeger
Journal:  Sci Rep       Date:  2018-06-22       Impact factor: 4.379

10.  An NAD+ Phosphorylase Toxin Triggers Mycobacterium tuberculosis Cell Death.

Authors:  Diana Mendes Freire; Claude Gutierrez; Acely Garza-Garcia; Anna D Grabowska; Ambre J Sala; Kanchiyaphat Ariyachaokun; Terezie Panikova; Katherine S H Beckham; André Colom; Vivian Pogenberg; Michele Cianci; Anne Tuukkanen; Yves-Marie Boudehen; Antonio Peixoto; Laure Botella; Dmitri I Svergun; Dirk Schnappinger; Thomas R Schneider; Pierre Genevaux; Luiz Pedro Sorio de Carvalho; Matthias Wilmanns; Annabel H A Parret; Olivier Neyrolles
Journal:  Mol Cell       Date:  2019-02-18       Impact factor: 17.970

View more
  4 in total

1.  RNase E and HupB dynamics foster mycobacterial cell homeostasis and fitness.

Authors:  Anna Griego; Thibaut Douché; Quentin Giai Gianetto; Mariette Matondo; Giulia Manina
Journal:  iScience       Date:  2022-04-12

2.  BacPROTACs mediate targeted protein degradation in bacteria.

Authors:  Francesca E Morreale; Stefan Kleine; Julia Leodolter; Sabryna Junker; David M Hoi; Stepan Ovchinnikov; Anastasia Okun; Juliane Kley; Robert Kurzbauer; Lukas Junk; Somraj Guha; David Podlesainski; Uli Kazmaier; Guido Boehmelt; Harald Weinstabl; Klaus Rumpel; Volker M Schmiedel; Markus Hartl; David Haselbach; Anton Meinhart; Markus Kaiser; Tim Clausen
Journal:  Cell       Date:  2022-06-03       Impact factor: 66.850

3.  Structure of the mycobacterial ESX-5 type VII secretion system pore complex.

Authors:  Katherine S H Beckham; Christina Ritter; Grzegorz Chojnowski; Daniel S Ziemianowicz; Edukondalu Mullapudi; Mandy Rettel; Mikhail M Savitski; Simon A Mortensen; Jan Kosinski; Matthias Wilmanns
Journal:  Sci Adv       Date:  2021-06-25       Impact factor: 14.136

4.  The pMy vector series: A versatile cloning platform for the recombinant production of mycobacterial proteins in Mycobacterium smegmatis.

Authors:  Katherine S H Beckham; Sonja Staack; Matthias Wilmanns; Annabel H A Parret
Journal:  Protein Sci       Date:  2020-10-13       Impact factor: 6.725

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.